Match!
N.P.M. Rubini
Universidade Federal do Estado do Rio de Janeiro
Randomized controlled trialPlaceboCochrane LibraryOmalizumabPopulation
1Publications
0Citations
What is this?
Publications 1
Newest
#1N.P.M. Rubini (UNIRIO: Universidade Federal do Estado do Rio de Janeiro)
#2Luis Felipe Ensina (UNIFESP: Federal University of São Paulo)H-Index: 11
Last. Dirceu Solé (UNIFESP: Federal University of São Paulo)H-Index: 36
view all 5 authors...
Abstract Introduction Chronic spontaneous urticaria (CSU) affects approximately 1% of the population, affecting both children and adults. Omalizumab (Oma) is a therapeutic option for patients with refractory forms of CSU. Objectives To determine the effectiveness and safety of Oma in the treatment of CSU. Methods Systematic review (Cochrane Collaboration methodology) of randomized clinical trials comparing Oma to placebo in refractory CSU treatment. The search is based on MEDLINE; EMBASE, Centra...
Source
1